AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25736134 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin calcium
Number of subjects: 120
Study 25736134 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg atorvastatin calcium
Number of subjects: 120
Study 25736134 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 mg atorvastatin calcium)
Number of subjects: 120
Study 23931541 — intervention group
Group type: EXPERIMENTAL
Intervention: High physician-expressed uncertainty (female physician)
Number of subjects: 189
Study 23931541 — intervention group
Group type: COMPARATOR
Intervention: Low physician-expressed uncertainty (female physician)
Number of subjects: 189
Study 23931541 — intervention group
Group type: COMPARATOR
Intervention: High physician-expressed uncertainty (male physician)
Number of subjects: 189
Study 23931541 — intervention group
Group type: COMPARATOR
Intervention: Low physician-expressed uncertainty (male physician)
Number of subjects: 189
Study 20974459 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 427
Study 20974459 — intervention group
Group type: COMPARATOR
Intervention: Overweight/obese status (BMI ≥25.0)
Number of subjects: 427
Study 20974459 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 427
Study 20974459 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy-induced hypertension
Number of subjects: 427
Study 20974459 — intervention group
Group type: COMPARATOR
Intervention: Latinas (BMI by race interaction)
Number of subjects: 427
Study 19894299 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine sulfate (PK-Merz)
Number of subjects: 40
Study 19894299 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 40
Study 17446339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 27
Study 17446339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 14998802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-randomized trials (GRTs)
Number of subjects: 60
Study 11437017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 173
Study 11437017 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 173
Study 9709756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% (Voltaren)
Number of subjects: 52
Study 9709756 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone sodium phosphate 1% ophthalmic solution
Number of subjects: 52
Study 9709756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diclofenac and prednisolone
Number of subjects: 52
Study 7977070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (240 mg twice daily for 7 days)
Number of subjects: 34
Study 7977070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg 3 times daily for 10 days)
Number of subjects: 34
Study 7977070 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 34
Study 7977070 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 34
Study 7977070 — intervention group
Group type: COMPARATOR
Intervention: Sotalol and Amiodarone
Number of subjects: 34
Study 2535309 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF), 100 micrograms
Number of subjects: 35
Study 2535309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin, 200 micrograms
Number of subjects: 35
Study 2535309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside, 120 micrograms
Number of subjects: 35
Study 2535309 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine, 3 mg
Number of subjects: 35
Study 2535309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 54209 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 60
Study 54209 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 60
Study 31585978 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 20
Study 31585978 — intervention group
Group type: COMPARATOR
Intervention: Balance and Tone (Control)
Number of subjects: 20
Study 28009728 — intervention group
Group type: EXPERIMENTAL
Intervention: FOREseal (alginate staple‐line reinforcement)
Number of subjects: 380
Study 28009728 — intervention group
Group type: COMPARATOR
Intervention: Control (standard management)
Number of subjects: 380
Study 26508645 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast augmentation in the subglandular plane
Number of subjects: 34
Study 26508645 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 34
Study 23128283 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring with nurse-led telephone support (n = 187)
Number of subjects: 381
Study 23128283 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 194)
Number of subjects: 381
Study 23128283 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring with nurse-led telephone support
Number of subjects: 381
Study 21562712 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting intervention for 12 months
Number of subjects: 295
Study 19373930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory attention focused exercise (PD SAFEx)
Number of subjects: 46
Study 19373930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-limb aerobic training
Number of subjects: 46
Study 19373930 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 46
Study 17351806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 units)
Number of subjects: 68
Study 17351806 — intervention group
Group type: COMPARATOR
Intervention: Gabexate mesylate (600 mg)
Number of subjects: 68
Study 17351806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 68
Study 17351806 — intervention group
Group type: COMPARATOR
Intervention: Gabexate mesylate
Number of subjects: 68
Study 12605430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative Photofrin-photodynamic therapy (PDT)
Number of subjects: 0
Study 12605430 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging system performance
Number of subjects: 0
Study 12605430 — intervention group
Group type: EXPERIMENTAL
Intervention: Photofrin-PDT
Number of subjects: 0
Study 10702454 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg morphine
Number of subjects: 245
Study 10702454 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg morphine
Number of subjects: 245
Study 9356793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant selective decontamination (SD)
Number of subjects: 102
Study 8447205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with epinephrine, 20 ml, intermittent 8-hourly bolus injections
Number of subjects: 22
Study 8447205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2943816 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (HBX‐R) administered IM at 10 micrograms, 3 doses (0, 1 month, 6 months)
Number of subjects: 199
Study 2943816 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine (H‐B‐VAX) administered IM at 20 micrograms, 3 doses (0, 1 month, 6 months)
Number of subjects: 199
Study 31560577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports medicine physicians
Number of subjects: 4500
Study 31560577 — intervention group
Group type: COMPARATOR
Intervention: Family/internal medicine physicians
Number of subjects: 4500
Study 31560577 — intervention group
Group type: COMPARATOR
Intervention: Pediatricians
Number of subjects: 4500
Study 31560577 — intervention group
Group type: EXPERIMENTAL
Intervention: General physicians
Number of subjects: 4500
Study 29446377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide inhalation powder combined with fluticasone propionate aerosol (group D)
Number of subjects: 160
Study 27431995 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily trimethoprim-sulfamethoxazole (TS) prophylaxis
Number of subjects: 1400
Study 27431995 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chloroquine (CQ) prophylaxis
Number of subjects: 1400
Study 27431995 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of standard of care TS prophylaxis
Number of subjects: 1400
Study 24615137 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) alone
Number of subjects: 16
Study 24615137 — intervention group
Group type: COMPARATOR
Intervention: Artesunate (AS) in combination with sulfadoxine/pyrimethamine (SP)
Number of subjects: 16
Study 24615137 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (AS) and dihydroartemisinin (DHA)
Number of subjects: 16
Study 22537281 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 5 months
Number of subjects: 150
Study 22537281 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 22537281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 150
Study 20451689 — intervention group
Group type: EXPERIMENTAL
Intervention: RVAP (n = 28)
Number of subjects: 93
Study 20451689 — intervention group
Group type: EXPERIMENTAL
Intervention: RVSP (n = 32)
Number of subjects: 93
Study 20451689 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 21)
Number of subjects: 93
Study 18547983 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF) after surgical management
Number of subjects: 0
Study 18547983 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF) offered sooner to older patients or those with more severe disease
Number of subjects: 0
Study 18547983 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of endometriomas
Number of subjects: 0
Study 16287402 — intervention group
Group type: EXPERIMENTAL
Intervention: Food, Mood, and Attitude (FMA) intervention
Number of subjects: 240
Study 16287402 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 12573690 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment
Number of subjects: 79
Study 12573690 — intervention group
Group type: COMPARATOR
Intervention: Outpatient addiction counseling
Number of subjects: 79
Study 10389026 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins (400 micrograms folic acid + 1.65 mg pyridoxine + 3 micrograms cyanocobalamin)
Number of subjects: 0
Study 10389026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9060347 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (time in situ ≤ 24 hours)
Number of subjects: 120
Study 9060347 — intervention group
Group type: COMPARATOR
Intervention: Control group (current/daily routines)
Number of subjects: 120
Study 1650406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 0
Study 1650406 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 1650406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Low-molecular-weight heparin and Unfractionated heparin)
Number of subjects: 0
Study 1650406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin and Unfractionated heparin
Number of subjects: 0
Study 7104806 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine
Number of subjects: 3
Study 7104806 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg epidural morphine
Number of subjects: 3
Study 7104806 — intervention group
Group type: COMPARATOR
Intervention: 0 mg (saline control)
Number of subjects: 3
Study 30915471 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + green-MED diet
Number of subjects: 294
Study 30915471 — intervention group
Group type: EXPERIMENTAL
Intervention: FG14
Number of subjects: 294
Study 30915471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mankai 50
Number of subjects: 294
Study 30915471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mankai 80
Number of subjects: 294
Study 30915471 — intervention group
Group type: EXPERIMENTAL
Intervention: FG9.5
Number of subjects: 294
Study 30915471 — intervention group
Group type: EXPERIMENTAL
Intervention: Mankai 50-C
Number of subjects: 294
Study 30915471 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 294
Study 29309599 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction (SGR) program
Number of subjects: 40
Study 29309599 — intervention group
Group type: COMPARATOR
Intervention: Control (non-SGR text messaging support)
Number of subjects: 40
Study 27409799 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX solution with SRP
Number of subjects: 120
Study 27409799 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX gel with SRP
Number of subjects: 120
Study 27409799 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX chip with SRP
Number of subjects: 120
Study 27409799 — intervention group
Group type: COMPARATOR
Intervention: Control SRP
Number of subjects: 120
Study 25544509 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 141
Study 25544509 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil 75 mg
Number of subjects: 141
Study 25544509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 22929677 — intervention group
Group type: EXPERIMENTAL
Intervention: Detralex (1,000 mg daily for 2 weeks prior and 4 weeks after endovascular treatment)
Number of subjects: 230
Study 22929677 — intervention group
Group type: COMPARATOR
Intervention: Conventional compression therapy (compression bandages or medicinal knitted fabric)
Number of subjects: 230
Study 20674884 — intervention group
Group type: EXPERIMENTAL
Intervention: Music presented in a major (happy) key
Number of subjects: 0
Study 20674884 — intervention group
Group type: EXPERIMENTAL
Intervention: Music presented in a minor (sad) key
Number of subjects: 0
Study 20674884 — intervention group
Group type: COMPARATOR
Intervention: Sine wave control music
Number of subjects: 0
Study 17272737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced written consent procedure
Number of subjects: 0
Study 17272737 — intervention group
Group type: EXPERIMENTAL
Intervention: Slideshow presentation
Number of subjects: 0
Study 15663066 — intervention group
Group type: EXPERIMENTAL
Intervention: Message campaign about hand hygiene and availability of gel hand sanitizer
Number of subjects: 0
Study 15663066 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 12858132 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (initial dose of 25 mg/day to a target dose of 100 mg BID)
Number of subjects: 70
Study 12858132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 10235193 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (10 sliced cloves)
Number of subjects: 12
Study 10235193 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (6 sliced fresh jalapeños)
Number of subjects: 12
Study 10235193 — intervention group
Group type: COMPARATOR
Intervention: Bismuth subsalicylate (2 tablets of Pepto-Bismol, positive control)
Number of subjects: 12
Study 10235193 — intervention group
Group type: COMPARATOR
Intervention: Nothing added (negative control)
Number of subjects: 12
Study 9074893 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol tablets (two lots)
Number of subjects: 5
Study 1751620 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPP (0.25 mg/kg)
Number of subjects: 7
Study 7047172 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline 4 mg tid for 7 days
Number of subjects: 40
Study 7047172 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg bid for 7 days
Number of subjects: 40
Study 7047172 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (continued treatment for 7 days)
Number of subjects: 40
Study 7047172 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (continued treatment for 7 days)
Number of subjects: 40
Study 31017513 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker-based RSA
Number of subjects: 57
Study 31017513 — intervention group
Group type: COMPARATOR
Intervention: Model-based RSA
Number of subjects: 57
Study 31017513 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene insert micromotion
Number of subjects: 57
Study 31017513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall migration data pooling
Number of subjects: 57
Study 31017513 — intervention group
Group type: EXPERIMENTAL
Intervention: Translations
Number of subjects: 57
Study 28285644 — intervention group
Group type: EXPERIMENTAL
Intervention: 5g transdermal testosterone gel (TT) daily for 12 months
Number of subjects: 37
Study 28285644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg oral aromatase inhibitor (AI) daily for 12 months
Number of subjects: 37
Study 28285644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 25231884 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, theory‐based nutrition education workshops focusing on dietary fat and brain health
Number of subjects: 0
Study 25231884 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, theory‐based nutrition education workshops focusing only on dietary fat and heart health
Number of subjects: 0
Study 25231884 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 25231884 — intervention group
Group type: COMPARATOR
Intervention: Posttest only control group
Number of subjects: 0
Study 24438121 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTX‐A (Chinese type A botulinum toxin)
Number of subjects: 20
Study 24438121 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 20
Study 21993890 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (300 mmol sodium/day; 17.5 g salt/day)
Number of subjects: 21
Study 21993890 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake (30 mmol sodium/day; 1.8 g salt/day)
Number of subjects: 21
Study 19142669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patches
Number of subjects: 28
Study 19142669 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 28
Study 17298413 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour lecture on root canal instrumentation
Number of subjects: 148
Study 17298413 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour lecture + 6-hour hands-on training
Number of subjects: 148
Study 11145439 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) induction treatment
Number of subjects: 30
Study 11145439 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) maintenance treatment
Number of subjects: 30
Study 8967887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallback I algorithm (Chorus I, Ela Medical Inc.)
Number of subjects: 45
Study 1360698 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal group (imagery rehearsal technique)
Number of subjects: 20
Study 1360698 — intervention group
Group type: COMPARATOR
Intervention: Recording group (no other intervention)
Number of subjects: 20
Study 2857610 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (alpha 2‐agonist)
Number of subjects: 6
Study 2857610 — intervention group
Group type: COMPARATOR
Intervention: Idazoxan (alpha 2‐antagonist)
Number of subjects: 6
Study 30398039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification group
Number of subjects: 744
Study 30398039 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin group
Number of subjects: 744
Study 30398039 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 744
Study 29405359 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive very-low-calorie diet (2 consecutive days)
Number of subjects: 41
Study 29405359 — intervention group
Group type: COMPARATOR
Intervention: Non-consecutive very-low-calorie diet (2 non-consecutive days)
Number of subjects: 41
Study 27357800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body heating (LBH)
Number of subjects: 18
Study 27357800 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral thigh heating (TH)
Number of subjects: 18
Study 27357800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 24450471 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut enriched ADA meal plan (20% of energy from peanuts)
Number of subjects: 60
Study 24450471 — intervention group
Group type: COMPARATOR
Intervention: Peanut-free ADA meal plan (control group)
Number of subjects: 60
Study 24450471 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss in entire cohort
Number of subjects: 60
Study 22950522 — intervention group
Group type: COMPARATOR
Intervention: GLPG0259 single ascending doses (1.5-150 mg)
Number of subjects: 70
Study 22950522 — intervention group
Group type: COMPARATOR
Intervention: GLPG0259 multiple doses (20 and 50 mg once daily)
Number of subjects: 70
Study 22950522 — intervention group
Group type: COMPARATOR
Intervention: GLPG0259 multiple doses (25-75 mg once daily for 14 days)
Number of subjects: 70
Study 22950522 — intervention group
Group type: COMPARATOR
Intervention: GLPG0259 solid dosage form
Number of subjects: 70
Study 22950522 — intervention group
Group type: COMPARATOR
Intervention: GLPG0259
Number of subjects: 70
Study 22950522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20021522 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 151
Study 20021522 — intervention group
Group type: COMPARATOR
Intervention: Quarterly device interrogations in clinic (Control)
Number of subjects: 151
Study 20021522 — intervention group
Group type: COMPARATOR
Intervention: Control (Quarterly device interrogations in clinic)
Number of subjects: 151
Study 17511187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent epidural fentanyl
Number of subjects: 50
Study 17511187 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous pethidine
Number of subjects: 50
Study 16139629 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11941270 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 709
Study 11941270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709